小鼠抗STK38L單克隆抗體

Background:

The nuclear Dbf2-related kinases (NDR-1 and NDR-2) participate in the regulation of cell division and morphology, and may be implicated in tumor progression. NDR-1 and NDR-2 share 86% amino acid identity, but differ in their expression pattern. NDR-1 localizes to the nucleus, while NDR-2 exhibits punctate cytoplasmic distribution. Also, NDR-1 expression appears highest in spleen, lung and thymus, whereas NDR-2 shows highest expression in the gastrointestinal tract. However, both NDR-1 and NDR-2 are regulated by phosphorylation and by the Ca2+-binding protein S100B. NDR-1 and NDR-2 may also play a role in the HIV-1 life cycle. Both proteins are cleaved by the HIV-1 protease (PR), which inhibits their enzymatic activity and alters the subcellular localization of NDR-2. The genes encoding human NDR-1 and NDR-2 map to chromosomes 6p21 and 12p11.23, respectively.

Applications:

WB, IHC, IF

Name of antibody:

STK38L

Immunogen:

Fusion protein of human STK38L

Full name:

serine/threonine kinase 38 like (STK38L)

Synonyms:

NDR2

SwissProt:

Q9Y2H1

IHC positive control:

human colon tissue and human liver tissue; adenocarcinoma of human ovary tissue and human breast tissue

IHC Recommend dilution:

30-150

WB Predicted band size:

54 kDa

WB Positive control:

HepG2, Hela, SVT2, A549, COS7, Jurkat, MDCK, PC12, MCF-7 cell lysates

WB Recommended dilution:

200-1000